

Which patients with myelofibrosis should receive ruxolitinib: evidence-based recommendations

Leukemia

31, 882-888

DOI: [10.1038/leu.2016.283](https://doi.org/10.1038/leu.2016.283)

Citation Report

#	ARTICLE	IF	CITATIONS
1	JAK2 inhibitors for myeloproliferative neoplasms: what is next?. <i>Blood</i> , 2017, 130, 115-125.	0.6	86
2	Managing side effects of JAK inhibitors for myelofibrosis in clinical practice. <i>Expert Review of Hematology</i> , 2017, 10, 617-625.	1.0	29
3	Treatment of Myelofibrosis: Old and New Strategies. <i>Clinical Medicine Insights Blood Disorders</i> , 2017, 10, 1179545X1769523.	0.3	21
4	Ruxolitinib for the management of myelofibrosis: Results of an international physician survey. <i>Leukemia Research</i> , 2017, 61, 6-9.	0.4	5
5	Actualit�s th�rapeutiques dans les n�oplasies my�loprolif�ratives non LMC. <i>Revue Francophone Des Laboratoires</i> , 2017, 2017, 59-62.	0.0	0
6	The <i>BCR-ABL1</i>-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1929-1938.	0.9	15
7	Advancing a field by building consortia: The example of the European LeukemiaNet. <i>Cancer</i> , 2018, 124, 1100-1104.	2.0	1
8	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. <i>Leukemia</i> , 2018, 32, 1057-1069.	3.3	415
9	The role of JAK2 inhibitors in MPNs 7 years after approval. <i>Blood</i> , 2018, 131, 2426-2435.	0.6	40
10	Efficacy and safety of ruxolitinib in intermediate- to high IPSS risk myelofibrosis patients: Results from an independent study. <i>Hematological Oncology</i> , 2018, 36, 285-290.	0.8	29
11	Recommendations on the use of ruxolitinib for the treatment of myelofibrosis. <i>Hematology</i> , 2018, 23, 194-200.	0.7	2
12	SOHO State-of-the-Art Update and Next Questions: MPN. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 1-12.	0.2	7
13	Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea. <i>Blood Cancer Journal</i> , 2018, 8, 122.	2.8	25
14	Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018. <i>Blood Cancer Journal</i> , 2018, 8, 64.	2.8	47
15	Ruxolitinib therapy for myelofibrosis in Austria. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 495-504.	1.0	5
16	Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study. <i>Journal of Hematology and Oncology</i> , 2018, 11, 101.	6.9	20
17	Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis. <i>Annals of Hematology</i> , 2019, 98, 1933-1936.	0.8	5
18	Impact of ruxolitinib on myelofibrosis patients post allogeneic stem cell transplant: a pilot study. <i>British Journal of Haematology</i> , 2019, 186, e130-e133.	1.2	9

#	ARTICLE	IF	CITATIONS
19	SOHO State of the Art Updates and Next Questions: Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 191-199.	0.2	1
20	MF management. HemaSphere, 2019, 3, 149-152.	1.2	1
21	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. Annals of Hematology, 2019, 98, 889-896.	0.8	10
22	The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review. Bone Marrow Transplantation, 2020, 55, 708-716.	1.3	23
23	JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives. HemaSphere, 2020, 4, e424.	1.2	49
24	Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-world practice. Annals of Hematology, 2020, 99, 65-72.	0.8	13
25	Management of Myelofibrosis: from Diagnosis to New Target Therapies. Current Treatment Options in Oncology, 2020, 21, 46.	1.3	8
26	Management of myelofibrosis after ruxolitinib failure. Leukemia and Lymphoma, 2020, 61, 1797-1809.	0.6	13
27	Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice. Leukemia, 2021, 35, 454-467.	3.3	27
28	Low-dose ruxolitinib shows effective in treating myelofibrosis. Annals of Hematology, 2021, 100, 135-141.	0.8	4
29	Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function. Platelets, 2022, 33, 404-415.	1.1	13
30	Standard care and investigational drugs in the treatment of myelofibrosis. Drugs in Context, 2019, 8, 1-16.	1.0	4
33	A Cross-sectional Study of Patients and Physicians on the Impact of Myeloproliferative Neoplasms on Patient Health: The Landmark Survey From Taiwan. Journal of Patient Experience, 2021, 8, 237437352110590.	0.4	2
34	Disease Modification in Myelofibrosis: An Elusive Goal?. Journal of Clinical Oncology, 2022, 40, 1147-1154.	0.8	12
35	Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematology, the, 2022, 9, e301-e311.	2.2	46
36	Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review. Future Oncology, 2022, 18, 2217-2231.	1.1	7
39	Pharmacotherapeutic advances for splenomegaly in myelofibrosis. Expert Opinion on Pharmacotherapy, 2023, 24, 577-585.	0.9	0
40	Ph-Negative Chronic Myeloproliferative Neoplasms. , 2024, , .		0